The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD).  The Orphan Drug Designation was supported by preliminary data from ReAlta’s ongoing Phase II trial, which included data from the initial cohort of steroid-refractory acute GvHD (aGvHD) patients.   The company is currently enrolling the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!